冠昊生物(300238) - 2020 Q1 - 季度财报

Financial Performance - Total revenue for Q1 2020 was ¥93,348,010.41, a decrease of 12.99% compared to ¥107,281,656.86 in the same period last year[8] - Net profit attributable to shareholders increased by 17.38% to ¥11,549,674.96 from ¥9,839,357.62 year-on-year[8] - Net profit excluding non-recurring gains and losses surged by 7,656.71% to ¥8,779,539.66, compared to a loss of ¥116,182.06 in the previous year[8] - The company's revenue for Q1 2020 was CNY 93.35 million, a decrease of 12.99% compared to the same period last year[21] - The net profit attributable to shareholders for Q1 2020 was CNY 11.55 million, an increase of 17.38% year-on-year[21] - Net profit for Q1 2020 was CNY 10,419,474.69, an increase from CNY 6,968,697.84 in the same period last year[45] - The total profit for the current period is ¥6,732,474.69, up 174.5% from ¥2,456,632.03 in the previous period[47] Cash Flow - Net cash flow from operating activities improved by 32.66%, reaching -¥16,563,348.15, compared to -¥24,596,566.99 in the same period last year[8] - The company reported a net cash outflow from operating activities of ¥16,563,348.15, an improvement from a net outflow of ¥24,596,566.99 in the previous period[53] - The company received cash from sales of goods and services amounting to ¥49,328,450.75, an increase from ¥36,514,659.40 in the previous period[55] - The company’s total operating cash inflow for the current period is ¥57,626,335.11, down from ¥131,485,888.28 in the previous period[55] - Cash outflows from operating activities totaled 69,437,211.12, down from 129,858,684.09 in the previous year, reflecting improved cash management[56] - The cash inflow from financing activities was 80,000,000.00, indicating strong support for the company's financial position[56] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,173,735,981.28, reflecting a 2.12% increase from ¥1,149,347,790.02 at the end of the previous year[8] - The company's total assets amounted to CNY 1,173,735,981.28, an increase from CNY 1,149,347,790.02 as of December 31, 2019[36] - The company's total liabilities were CNY 457,898,286.74, compared to CNY 445,211,628.42 at the end of the previous year, indicating a rise of approximately 2.5%[37] - Total liabilities rose to CNY 485,203,615.08 from CNY 452,332,547.19[41] Shareholder Information - The company reported a total of 30,587 common shareholders at the end of the reporting period[11] - Guangdong Zhiguang Biotechnology Co., Ltd. held 20.76% of shares, with 55,044,822 shares pledged[11] - The company did not engage in any repurchase transactions among the top 10 shareholders during the reporting period[12] - The controlling shareholder completed a share buyback plan, acquiring 3,019,032 shares, representing 1.14% of the total share capital[28] Expenses - Financial expenses increased by 63.62% year-on-year, due to the absence of foreign exchange gains recognized in the previous year[19] - The company implemented cost-cutting measures, resulting in a 26.66% reduction in sales expenses and a 36.62% reduction in management expenses compared to the previous year[19] - Research and development expenses were CNY 7,281,481.16, down from CNY 9,149,465.90[44] - Research and development expenses for the current period are ¥2,136,951.61, slightly down from ¥2,297,117.44 in the previous period[47] Agreements and Operations - The company signed an exclusive distribution agreement with Arren Scientific, Inc. extending to December 31, 2023, benefiting its ophthalmology division[22] - The marketing team actively expanded sales channels and utilized online platforms for public education during the pandemic, generating CNY 9.75 million in sales for a specific product[24] Compliance and Audits - The company did not undergo an audit for the first quarter report, which may affect the reliability of the financial data presented[58] - The company did not apply new revenue and leasing standards for the current year, indicating continuity in accounting practices[58]